阿托伐他汀对急性冠脉综合征患者血清同型半胱氨酸水平的影响

Influence of atorvastatin on serum homocysteine in patients with acute coronary syndrome

目的观察阿托伐他汀对急性冠脉综合征(ACS)患者血清同型半胱氨酸(Hcy)水平的影响,探讨其治疗ACS的作用机理。方法将66例ACS患者随机分为治疗组和对照组,每组33例。对照组给予常规治疗,治疗组在此基础上加用阿托伐他汀钙40 mg/d口服治疗4周。在治疗前及治疗4周后分别检测两组血脂和Hcy水平。结果治疗组在治疗后的血清TC、TG、LDL-C和Hcy水平均较治疗前明显降低(P<0.01和P<0.05),而HDL-C则较治疗前明显升高(P<0.05),治疗组血清Hcy水平在治疗后较对照组明显降低(P<0.05)。对照组治疗前后的TC、TG、HDL-C、LDL-C及Hcy水平比较,差异均无统计学意义(P>0.05)。结论阿托伐他汀可通过降低ACS患者血脂及Hcy水平而发挥其抗动脉粥样硬化作用。

Objective To observe the influence of atorvastatin on serum homocysteine （Hcy） in patients with acute coronary syndrome （ACS）. Methods Sixty-six patients with ACS were divided randomly into therapy group and control group with each group of Thirty-three cases, both groups received conventional treatment, moreover, the therapy group was treated with orally atorvastatin 40 mg/d for four weeks. The levels of serum lipids and Hcy in both groups were detected before and after treatment of four weeks. Results Compared with before treatment, the serum level of TC, TG, LDL-C and Hcy dropped significantly（P＆lt;0.01 or P＆lt;0.05）, while HDL-C increased significantly（P＆lt;0.05） in therapy group. The Hcy level of therapy group after treatment was lower than the control significantly （P＆lt;0.05）. There were no significant difference of serum lipids and Hcy level between before and after treatment in control group（all P＆lt;0.05）. Conclusion Atorvastatin has action of anti-atherogensis by decreasing levels of serum lipids and Hcy in ACS patients.